Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT trial of polymerized grass + olive pollen allergoids in allergic rhinitis/rhinoconjunctivitis with or without mild to moderate asthma
2024-514525-34-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Aug 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mixture of modified allergen extracts of 6 grasses + modified allergen extract of olive pollen in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Inmunotek. Primary endpoint: Overall symptom and medication score during the grass and olive tree pollen season. Planned start Aug 2024; status: authorised.
02
Drugs
mixture of modified allergen extracts of 6 grasses + modified allergen extract of olive pollen
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2024-514525-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514525-34-00.